Opaleye Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Opaleye Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-669,944	Closed	-$918K	–	55
2023 Q2	$918K	Sell	669,944 -2,210,056	-77%	-$4.21M	0.22%	42
2023 Q1	$5.33M	Buy	+2,880,000	New	+$3.57M	1.6%	19

Opaleye Management's JNCE Position: Q3 2023 in Review

Opaleye Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2023, closing a stake of 669,944 shares — an estimated $918K sold.

Opaleye Management first reported a position in JNCE in Q1 2023 and held it in 2 quarters. The position peaked at $5.33M in Q1 2023. 0 funds tracked by Wall St. Rank hold JNCE as of Q3 2023.

Opaleye Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Opaleye Management sold 669,944 Jounce Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $918K.
Opaleye Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2023 and held it in 2 quarters.
Opaleye Management's Jounce Therapeutics, Inc. Common Stock position peaked at $5.33M in Q1 2023.
0 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Opaleye Management's 13F filing for Q3 2023, filed 15 Nov 2023.